WTR Biotech Spotlight

A Conversation with PharmAla Biotech CEO Nick Kadysh on What the Trump FDA and AI mean for the Biotech Landscape

Joe Brunetto Season 1 Episode 13

In this episode of the WTR Biotech Spotlight, Water Tower Research’s Tim Gerdeman is joined by Nick Kadysh, Founding CEO and President of Toronto-headquartered Life Sciences company, PharmAla Biotech (CSE: MDMA; OTCQB: MDXXF),and WTR Senior Analyst Robert Sassoon for an insightful discussion on arguably the two main topics that are currently concentrating the minds of  biotech industry folk: The implications of the Trump Administration's FDA reforms and  AI's role in reshaping the industry.

With over a decade of experience as a Public Affairs and Regulatory expert, Nick Kadysh founded PharmAla in 2020 to focus on the manufacturing and development of MDMA and MDMA-related molecules. Kadysh is also a prominent spokesman for the deployment of AI in drug discovery,